The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies.
S. O'Day
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
J. S. Weber
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Other Remuneration - Medarex
J. D. Wolchok
Consultant or Advisory Role - Bristol-Myers Squibb
J. M. Richards
Consultant or Advisory Role - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
P. Lorigan
No relevant relationships to disclose
D. F. McDermott
Consultant or Advisory Role - Bristol-Myers Squibb
W. J. Urba
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
V. DePril
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
K. N. Heller
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
R. A. Ibrahim
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
A. Hauschild
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb